Pluvicto (lutetium LU 177 vipivotide tetra 27MCI/ML)
Active Awarded Last action
- Contract number
- 36C24226N0216
- Awardee
-
Novartis Pharmaceuticals Corporation UEI NG61ZA8TADW3
- Awarding agency
-
Veterans Integrated Service Network 2
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $813,476
Award facts
- Opportunity
-
- 36C24226Q0080 Solicitation number
- Contract value 100% obligated
- $813,476.16 Current and potential, with all options
- Completion date 97% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- East Hanover, NJ 07936, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $514,414 | |
| Original award | $299,062 |
About this award
Novartis Pharmaceuticals Corporation received a $813,476.16 firm fixed-price delivery order from Veterans Integrated Service Network 2 (VISN 2) for PLUVICTO (Lutetium Lu-177 Vipivotide Tetra), a specialized radiopharmaceutical cancer therapy product. The delivery order, issued on November 1, 2025, with an ultimate completion date of October 31, 2026, falls under Novartis' existing Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) contract vehicle. The place of performance is East Hanover, New Jersey. No small business set-aside was utilized for this award, allowing Novartis to compete directly as a large pharmaceutical manufacturer in the federal marketplace.
This delivery order represents a continuation of Novartis' substantial role as a federal supplier of oncology and nuclear medicine treatments to the Department of Veterans Affairs. The company maintains multiple indefinite delivery vehicles supporting PLUVICTO procurement across the VA system, including a $7.48 million Blanket Purchase Agreement awarded by VISN 10 on October 1, 2025, extending through September 2030. PLUVICTO is used for advanced cancer therapies, particularly in supporting targeted radiopharmaceutical treatments for veterans and eligible beneficiaries within the VA healthcare system.
Quick answers
Who was awarded contract 36C24226N0216?
36C24226N0216 was awarded to Novartis Pharmaceuticals Corporation by Veterans Integrated Service Network 2 (Veterans Health Administration) on November 1, 2025.
How much is contract 36C24226N0216 worth?
The government has obligated $813,476 on 36C24226N0216.
Is contract 36C24226N0216 an order under another contract?
Yes. 36C24226N0216 is a delivery order under 36F79720D0180, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C24226N0216 competed?
The extent of competition for 36C24226N0216 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award